From this perspective, NSCLC patients who possibly represent acquired resistance to PD-1 mAb immunotherapy should be screened in early stage and the clincians are necessary to reconsider the application strategy of PD-1 mAbs for these patients. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.